



**Southwest
Oncology Group**
A National Clinical Research Group

April 1, 2003

TO: CCOP Principal Investigators
CCOP Clinical Research Associates

FROM: Dana B. Sparks, M.A.T. - Protocol Product Line Manager

RE: CCOP Protocol Credit Assignments

MEMORANDUM

An updated list (dated 2/20/03) that reflects the latest cancer control and treatment credits assigned to Southwest Oncology Group studies has been posted at <http://www3.cancer.gov/prevention/ccop>. A permanent link to this site has also been added to the "Links" page at [swog.org](http://www.swog.org).

Additionally, please see the attached letter from Dr. Joseph Kelaghan at the Division of Cancer Prevention, NCI regarding the change in credit assignment for S0002 to 1.0 cancer control credits – retroactive to 6/1/02.

Future updates will be forwarded as they are received in this office.

cc: Charles A. Coltman, Jr., M.D.
John J. Crowley, Ph.D.
Jacqueline Benedetti, Ph.D.
Evonne Lackey
Carol Moinpour, Ph.D.
Tiffanie Clausewitz
Marjorie Godfrey
Protocol Coordinators

Operations Office

14980 Omicron Drive • San Antonio, TX 78245-3217 • Telephone 210-677-8808 • FAX 210-677-0006 • <http://www.swog.org>



National Institutes of Health
National Cancer Institute
Bethesda, Maryland 20892

Community Oncology and
Prevention Trials Research Group
Executive Plaza North, Suite 2017
6130 EXECUTIVE BLVD, MSC-7340
BETHESDA, MD 20892-7340
PHONE: 301\496-8541
FAX: 301\496-8667

Date: March 13, 2003
Protocol S0002
Protocol Chair: Ellen R. Gritz, Ph.D.

Charles Coltman, Jr., M.D.
Southwest Oncology Group
SWOG Operations Office
14980 Omicron Drive
San Antonio, TX 78245-3217

RECEIVED
MAR 13 2003
OPERATIONS OFFICE

Dear Dr. Coltman:

The Division of Cancer Prevention has determined that the work involved in conducting SWOG's protocol "Smoking Cessation Intervention (including Bupropion-Zyban versus Placebo) for Completely Resected Stage I and II Non-Small Cell Lung Cancer Survivors Who are Current Smokers" justifies an increase in credit assignment for subjects accrued to this trial. This cancer control protocol will now receive 1.0 cancer control credits.

Please notify the CCOPs about this change in credit assignment. Also note that this new credit assignment is retroactive to all subjects accrued since June 1, 2002.

Sincerely,

Joseph Kelaghan, M.D.
Chair, Cancer Prevention and Control
Protocol Review Committee
Division of Cancer Prevention

cc: Ellen R. Gritz, Ph.D.